Contineum Therapeutics, Inc. SEC filings

Filings

1. 144Contineum Therapeutics, Inc.CTNMOct 1

   Daniel S. Lorrain, planned sale of CTNM shares

   Daniel S. Lorrain

2. 8-KContineum Therapeutics, Inc.CTNMSep 14

   Current report

3. 4Contineum Therapeutics, Inc.CTNMSep 8

   Carmine N. Stengone, insider filing for CTNM

   Carmine N. Stengone, reporting

4. 144Contineum Therapeutics, Inc.CTNMSep 8

   Carmine N. Stengone, planned sale of CTNM shares

   Carmine N. Stengone, reporting

5. 144Contineum Therapeutics, Inc.CTNMSep 1

   Daniel S. Lorrain, planned sale of CTNM shares

   Daniel S. Lorrain, reporting

6. SCHEDULE 13G/AContineum Therapeutics, Inc.CTNMAug 14

   Ownership stake disclosure by BALYASNY ASSET MANAGEMENT L.P. (amended)

   BALYASNY ASSET MANAGEMENT L.P., filed by

7. 4Contineum Therapeutics, Inc.CTNMAug 3

   Carmine N. Stengone, insider filing for CTNM

   Carmine N. Stengone, reporting

8. 144Contineum Therapeutics, Inc.CTNMAug 3

   2 Form 144 notices

   Carmine N. Stengone, planned sale of CTNM shares

   Show all 2

   • 144Planned insider sale of CTNM sharesAug 3
   • 144Planned insider sale of CTNM sharesAug 3

   Carmine N. Stengone, reporting

9. 10-QContineum Therapeutics, Inc.CTNMJul 30

   Quarterly report

10. 8-KContineum Therapeutics, Inc.CTNMJul 30

    Current report

11. SCHEDULE 13GContineum Therapeutics, Inc.CTNMJul 27

    Ownership stake disclosure by BlackRock, Inc.

    BlackRock, Inc., filed by

12. SCHEDULE 13G/AContineum Therapeutics, Inc.CTNMJul 17

    Ownership stake disclosure by MILLENNIUM MANAGEMENT LLC (amended)

    MILLENNIUM MANAGEMENT LLC, filed by

13. 8-KContineum Therapeutics, Inc.CTNMJul 13

    Current report

14. 4Contineum Therapeutics, Inc.CTNMJul 10

    Daniel S. Lorrain, insider filing for CTNM

    Daniel S. Lorrain, reporting

15. 4Contineum Therapeutics, Inc.CTNMJul 8

    Carmine N. Stengone, insider filing for CTNM

    Carmine N. Stengone, reporting

16. 144Contineum Therapeutics, Inc.CTNMJul 8

    Carmine N. Stengone, planned sale of CTNM shares

    Carmine N. Stengone, reporting

17. 4Contineum Therapeutics, Inc.CTNMJul 2

    Daniel S. Lorrain, insider filing for CTNM

    Daniel S. Lorrain, reporting

18. 4Contineum Therapeutics, Inc.CTNMJul 1

    2 insider filings

    Tim Watkins, insider filing for CTNM

    Show all 2

    • 4Insider filing for CTNMJul 1
    • 4Insider filing for CTNMJul 1

    Tim Watkins, reporting

19. 144Contineum Therapeutics, Inc.CTNMJul 1

    Daniel S. Lorrain, planned sale of CTNM shares

    Daniel S. Lorrain, reporting

20. 144Contineum Therapeutics, Inc.CTNMJun 30

    3 Form 144 notices

    Carmine N. Stengone, planned sale of CTNM shares

    Show all 3

    • 144Planned insider sale of CTNM sharesJun 30
    • 144Planned insider sale of CTNM sharesJun 30
    • 144Planned insider sale of CTNM sharesJun 30

    Carmine N. Stengone, reporting

21. 4Contineum Therapeutics, Inc.CTNMJun 26

    7 insider filings

    Gines Diego Miralles, insider filing for CTNM

    Show all 7

    • 4Insider filing for CTNMJun 26
    • 4Insider filing for CTNMJun 26
    • 4Insider filing for CTNMJun 26
    • 4Insider filing for CTNMJun 26
    • 4Insider filing for CTNMJun 26
    • 4Insider filing for CTNMJun 26
    • 4Insider filing for CTNMJun 26

    Gines Diego Miralles, reporting

22. 8-KContineum Therapeutics, Inc.CTNMJun 26

    Current report

23. 4Contineum Therapeutics, Inc.CTNMJun 1

    Daniel S. Lorrain, insider filing for CTNM

    Daniel S. Lorrain, reporting

24. 144Contineum Therapeutics, Inc.CTNMJun 1

    Daniel S. Lorrain, planned sale of CTNM shares

    Daniel S. Lorrain, reporting

25. SCHEDULE 13G/AContineum Therapeutics, Inc.CTNMMay 15

    Ownership stake disclosure by RA CAPITAL MANAGEMENT, L.P. (amended)

    RA CAPITAL MANAGEMENT, L.P., filed by

26. SCHEDULE 13GContineum Therapeutics, Inc.CTNMMay 15

    Ownership stake disclosure by BALYASNY ASSET MANAGEMENT L.P.

    BALYASNY ASSET MANAGEMENT L.P., filed by

27. 10-QContineum Therapeutics, Inc.CTNMMay 5

    Quarterly report

28. 8-KContineum Therapeutics, Inc.CTNMMay 5

    Current report

29. 4Contineum Therapeutics, Inc.CTNMMay 1

    Daniel S. Lorrain, insider filing for CTNM

    Daniel S. Lorrain, reporting

30. 144Contineum Therapeutics, Inc.CTNMMay 1

    Daniel S. Lorrain, planned sale of CTNM shares

    Daniel S. Lorrain, reporting

31. ARSContineum Therapeutics, Inc.CTNMApr 30

    Annual report to shareholders

32. DEFA14AContineum Therapeutics, Inc.CTNMApr 30

    Additional proxy materials

33. DEF 14AContineum Therapeutics, Inc.CTNMApr 30

    Proxy statement

34. 8-KContineum Therapeutics, Inc.CTNMApr 30

    Current report

35. SCHEDULE 13GContineum Therapeutics, Inc.CTNMApr 17

    Ownership stake disclosure by MILLENNIUM MANAGEMENT LLC

    MILLENNIUM MANAGEMENT LLC, filed by

36. 4Contineum Therapeutics, Inc.CTNMApr 6

    Daniel S. Lorrain, insider filing for CTNM

    Daniel S. Lorrain, reporting

37. 144Contineum Therapeutics, Inc.CTNMApr 6

    Daniel S. Lorrain, planned sale of CTNM shares

    Daniel S. Lorrain, reporting

38. S-8Contineum Therapeutics, Inc.CTNMMar 5

    Employee stock plan registration

39. 424B5Contineum Therapeutics, Inc.CTNMMar 5

    Securities offering

40. 10-KContineum Therapeutics, Inc.CTNMMar 5

    Annual report

Older filings on EDGAR